<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03786081</url>
  </required_header>
  <id_info>
    <org_study_id>GCT1015-05</org_study_id>
    <secondary_id>InnovaTV 205</secondary_id>
    <secondary_id>MK3475 KN 834</secondary_id>
    <nct_id>NCT03786081</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Tisotumab Vedotin Monotherapy &amp; in Combination With Other Cancer Agents in Subjects With Cervical Cancer</brief_title>
  <official_title>A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genmab</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Network of Gynaecological Oncological Trial Groups (ENGOT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Belgian Gynaecological Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genmab</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, multi-center trial of tisotumab vedotin monotherapy and in combination
      with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB
      cervical cancer.

      The trial consists of two-parts a dose escalation part and an expansion part. The expansion
      part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) of the
      combinations have been determined in the dose escalation part.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The dose escalation part will occur in cervical cancer subjects who have progressed during or
      after standard of care therapy and who are intolerant or ineligible to receive standard of
      care treatments. Arm A will be conducted by escalating doses of both tisotumab vedotin and
      bevacizumab. Dose escalations of the tisotumab vedotin + pembrolizumab and tisotumab vedotin
      + carboplatin combinations (Arms B and C, respectively) will be conducted by combining fixed
      doses of either pembrolizumab or carboplatin with increasing doses of tisotumab vedotin.

      The dose expansion part will consist of subjects with recurrent or stage IVB cervical cancer,
      who have not received prior systemic therapy for their recurrent or stage IVB disease, Arms D
      and E being treated with tisotumab vedotin + carboplatin or tisotumab vedotin +
      pembrolizumab, respectively, or subjects, who have progressed on or after standard of care
      treatments, Arm F treated with tisotumab vedotin + pembrolizumab and Arm G treated with
      tisotumab vedotin alone. Subjects enrolled to Arms D, E, and F will receive the RP2D of
      tisotumab vedotin established in the dose escalation part. Subjects enrolled to Arm G will
      receive tisotumab vedotin weekly for three weeks and 1 week off (28 day treatment cycle).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose escalation: Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>DLTs will be identified during the first treatment cycles (21 days cycles)</time_frame>
    <description>To establish the MTD and RP2D of tisotumab vedotin in combination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose expansion: Evaluate the antitumor activity of tisotumab vedotin monotherapy and in combination in subjects with cervical cancer</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Objective Response Rate (ORR) based upon RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Frequency, duration, and severity of adverse events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Objective Response Rate (ORR) based upon RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Duration of Response (DOR) based upon RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Time to Response (TTR) based upon RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Progression free survival (PFS) based upon RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Overall Survival (OS)</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>A: Tisotumab Vedotin + bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation: Tisotumab vedotin in combination with bevacizumab once every three weeks in previously treated patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Tisotumab vedotin + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously treated patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: Tisotumab vedotin + carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation: Tisotumab vedotin in combination with carboplatin once every three weeks in previously treated patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D: Tisotumab vedotin + carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose expansion:Tisotumab vedotin in combination with carboplatin once every three weeks in previously untreated patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E: Tisotumab vedotin + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose expansion: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously untreated patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F: Tisotumab vedotin + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose expansion: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously treated patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G: Tisotumab vedotin monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose expansion: Tisotumab vedotin monotherapy weekly for three weeks and 1 week off (28 day treatment cycle) in previously treated patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tisotumab Vedotin</intervention_name>
    <description>i.v.</description>
    <arm_group_label>A: Tisotumab Vedotin + bevacizumab</arm_group_label>
    <arm_group_label>B: Tisotumab vedotin + pembrolizumab</arm_group_label>
    <arm_group_label>C: Tisotumab vedotin + carboplatin</arm_group_label>
    <arm_group_label>D: Tisotumab vedotin + carboplatin</arm_group_label>
    <arm_group_label>E: Tisotumab vedotin + pembrolizumab</arm_group_label>
    <arm_group_label>F: Tisotumab vedotin + pembrolizumab</arm_group_label>
    <arm_group_label>G: Tisotumab vedotin monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>i.v.</description>
    <arm_group_label>A: Tisotumab Vedotin + bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>i.v.</description>
    <arm_group_label>B: Tisotumab vedotin + pembrolizumab</arm_group_label>
    <arm_group_label>E: Tisotumab vedotin + pembrolizumab</arm_group_label>
    <arm_group_label>F: Tisotumab vedotin + pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>i.v.</description>
    <arm_group_label>C: Tisotumab vedotin + carboplatin</arm_group_label>
    <arm_group_label>D: Tisotumab vedotin + carboplatin</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have squamous, adenosquamous, or adenocarcinoma of the cervix and progressed on
             or after standard of care treatments or are ineligible or intolerant to standard of
             care for recurrent or stage IVB cervical cancer (Arms A, B and C only).

          -  Must have squamous, adenosquamous, or adenocarcinoma of the cervix and must not have
             received prior systemic therapy for recurrent or stage IVB cervical cancer (Arms D and
             E only).

          -  Must have squamous, adenosquamous, or adenocarcinoma of the cervix and progressed on
             or after at least one but no more than two prior systemic therapies for recurrent or
             stage IVB cervical cancer (Arm F and G only).

          -  Must have baseline measurable disease per RECIST v1.1.

          -  Must be at least 18 years of age on the day of signing informed consent (All Arms).

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (All
             Arms).

          -  Is not pregnant, breastfeeding, or expecting to conceive children within the projected
             duration of the trial and for at least 6 months after the last trial treatment
             administration

          -  Women of childbearing potential must agree to use adequate contraception during and
             for 6 months after the last dose of trial treatment administration.

          -  Must sign an informed consent form (ICF) indicating the trial subject understands the
             purpose of and procedures required for the trial and are willing to participate in the
             trial (All Arms).

        Exclusion Criteria:

          -  Has clinically relevant bilateral hydronephrosis which cannot be alleviated by
             ureteral stents or percutaneous drainage. (All Arms)

          -  Has clinical signs or symptoms of gastrointestinal obstruction and requires parenteral
             hydration and/or nutrition. Post-operative obstructions within 4 weeks of abdominal
             surgery are permitted. (All Arms)

          -  Has clinically significant bleeding issues or risks

          -  Prior history (within 3 months) or current evidence of hemoptysis (1/2 teaspoon or
             more) (Arm A only)

          -  Recent (within 4 weeks of first dose of trial treatment) clinically significant
             gastrointestinal or vaginal bleeding requiring PRBC transfusion (Arm A only)

          -  Recent (within 4 weeks of first dose of trial treatment) evidence of wound healing
             complications that require medical intervention (Arm A only)

          -  Has active ocular surface disease at baseline. Subjects with prior history of
             cicatricial conjunctivitis are ineligible (All Arms).

          -  Clinically significant cardiac disease

          -  Requires anti-coagulation therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Genmab A/S Trial Information</last_name>
    <phone>+4570202728</phone>
    <email>clinicaltrials@genmab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Univ California, Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Richards</last_name>
      <phone>714-509-9719</phone>
      <email>srichar4@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Krishnansu Tewari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Olive View - UCLA Research and Education Institute</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Biana Alcantar</last_name>
      <phone>818-364-3222</phone>
      <email>bialcantar@dhs.lacounty.gov</email>
    </contact>
    <investigator>
      <last_name>Christine Holschneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist MD Anderson Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Sakin</last_name>
      <phone>904-202-7455</phone>
      <email>sarah.sakin@bmcjax.com</email>
    </contact>
    <investigator>
      <last_name>Jenny Whitworth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60525</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Penny Dolan</last_name>
      <phone>773-702-3394</phone>
      <email>pdolan@babies.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>John Moroney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Alvey</last_name>
      <phone>317-278-6455</phone>
      <email>rlalvey@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Jeanne Schilder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Kreutzjans</last_name>
      <phone>913-945-7549</phone>
      <email>akreutzjans@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Andrea Jewell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oschner Clinic</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina Wade, MD</last_name>
      <phone>504-842-4165</phone>
      <email>katrina.wade@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Katrina Wade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Engvold</last_name>
      <phone>617-632-2164</phone>
      <email>vengvold@partners.org</email>
    </contact>
    <investigator>
      <last_name>Susanna Campos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montana Cancer Consortium</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Allen</last_name>
      <phone>406-435-7489</phone>
      <email>lallen@billingsclinic.org</email>
    </contact>
    <investigator>
      <last_name>Justin Bottsford-Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen-Ching Lee</last_name>
      <phone>718-270-2365</phone>
      <email>wen-ching.lee@downstate.edu</email>
    </contact>
    <investigator>
      <last_name>Yi-Chun Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Guillen</last_name>
      <phone>646-735-8278</phone>
      <email>guillenj@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Roisin O'Cearbhaill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Gruhn</last_name>
      <phone>919-455-4212</phone>
      <email>jennifer_gruhn@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Linda Van Le, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Physicians Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynea Bach</last_name>
    </contact>
    <investigator>
      <last_name>Amanda Jackson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Licina</last_name>
      <phone>216-445-5394</phone>
      <email>licinac@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Peter Rose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Hilliard</city>
        <state>Ohio</state>
        <zip>43026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Myers</last_name>
      <phone>614-685-6411</phone>
      <email>Molly.Myers@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>David O'Malley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittney Cirone</last_name>
      <phone>215-214-1667</phone>
      <email>Brittney.Cirone@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>Christina Chu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's and Infant Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Mari</last_name>
      <phone>401-274-1122</phone>
      <phone_ext>48181</phone_ext>
      <email>jmari@wihri.org</email>
    </contact>
    <investigator>
      <last_name>Cara Mathews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Francis Hospital Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Sanchez</last_name>
      <phone>864-225-5131</phone>
      <email>Christine_sanchez@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>David Griffin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carilion Clinic</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Selvia</last_name>
      <phone>540-581-0240</phone>
      <email>djselvia@carilionclinic.org</email>
    </contact>
    <investigator>
      <last_name>David Iglesias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelique Slock</last_name>
    </contact>
    <investigator>
      <last_name>Eveline DeCuypere, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise Favaretto</last_name>
      <phone>+32 2 764 35 13</phone>
      <email>louise.favaretto@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Jean-Francois Baurain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Clue</last_name>
    </contact>
    <investigator>
      <last_name>Hannelore Denys, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven,</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Vantilt</last_name>
      <phone>+32 16 34 19 07</phone>
      <email>bo.vantilt@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Ignace Vergote, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maude Piron</last_name>
      <phone>+32 4 366 82 50</phone>
      <email>mpiron@chuliege.be</email>
    </contact>
    <investigator>
      <last_name>Christine Gennigens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sainte-Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benedicte Hyernaux</last_name>
    </contact>
    <investigator>
      <last_name>Stephanie Henri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aneta Nenickova</last_name>
      <phone>+420 224967 452</phone>
      <email>aneta.nenickova@fno.cz</email>
    </contact>
    <investigator>
      <last_name>Jaroslav Flat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Praha 2</city>
        <zip>12851</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivana Nohova</last_name>
      <phone>+420 224 969 298</phone>
      <email>Ivana.nohova@vfn.cz</email>
    </contact>
    <investigator>
      <last_name>David Cibula, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Bulovce</name>
      <address>
        <city>Praha</city>
        <zip>18081</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stepanka Kupcova</last_name>
      <phone>+420266084223</phone>
      <email>kupcovas@seznam.cz, stepanka.kupcova@bulovka.cz</email>
    </contact>
    <investigator>
      <last_name>Michal Zikan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>5072</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ane Taudorf Nørmark</last_name>
      <phone>+45 3545 6997</phone>
      <email>ane.taudorf.noermark.01@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Mansoor Mirza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristen Madsen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edel Hassett</last_name>
      <phone>086-1728701</phone>
      <email>Edel.hassett@hse.ie</email>
    </contact>
    <investigator>
      <last_name>Dearbhaile Collins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>D07 R2WY D</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Smith</last_name>
      <phone>8034838</phone>
      <email>msmith@mater.ie</email>
    </contact>
    <investigator>
      <last_name>Catherine M Kelly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Waterford</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flordeliza Calacsan</last_name>
      <phone>+353 51 848590</phone>
      <email>Flordeliza.calacsan@hse.ie</email>
    </contact>
    <investigator>
      <last_name>Paula Calvert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiara Alonzi</last_name>
      <phone>+39688818881</phone>
      <email>chiara.alonzi@policlinicogemelli.it</email>
    </contact>
    <contact_backup>
      <last_name>Dominique Ronzulli</last_name>
      <phone>+39688818881</phone>
      <email>dominique.ronzulli@istitutotumori.mi.it</email>
    </contact_backup>
    <investigator>
      <last_name>Domenica Lorusso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMC Medical Research</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva VanDalen</last_name>
      <email>trialmedonc@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lyda ter Hofstede</last_name>
      <email>trialmedonc@amc.uva.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Anneke Westermann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B.T. Smit-Aeikema</last_name>
      <phone>+31 50 361 3919</phone>
      <email>b.t.smit@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>An Reyners, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elin Smits, RN</last_name>
      <phone>+31243611111</phone>
      <email>Elin.smits@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Laura Dobbe, RN</last_name>
      <email>laura.dobbe@radboudumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Petronella Ottevanger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Bolder</last_name>
      <phone>+310107034897</phone>
      <email>c.bolder@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Ingrid Boere, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht (UMC Utrecht)</name>
      <address>
        <city>Utrecht</city>
        <zip>3584</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellis van Liempt</last_name>
      <email>oncology-trialssecretariat@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>Eelke Gort, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Centre</name>
      <address>
        <city>Cardiff</city>
        <state>South Glamorgan</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Halpin</last_name>
      <phone>+442920316206</phone>
      <email>Jill.Halpin@wales.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Robert Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Strathclyde</state>
        <zip>G12 OYN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina McLean</last_name>
      <phone>+441413017068</phone>
      <email>Katrina.McLean@glasgow.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Azmat Sadozye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital- Sutton</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Hamill</last_name>
      <phone>+442086613979</phone>
      <email>Monica.Hamill@rmh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Samantha Walton</last_name>
      <phone>+442086613979</phone>
      <email>samantha.walton@rmh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Susana Banerjee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 13, 2018</study_first_submitted>
  <study_first_submitted_qc>December 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2018</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cervical carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

